EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Malaria, a disease responsible for over one million deaths per year, is caused by a germ
spread by mosquito bites. The purpose of this study is to evaluate a vaccine designed for the
prevention of malaria caused by the parasite, Plasmodium falciparum, and to evaluate the
device used to give the vaccine. This study will provide information on how safe, effective,
and tolerable the vaccine is in healthy adults. The participants will be assigned, by chance,
to receive 3 doses/shots of the vaccine or a placebo (substance that contains no medication)
by injection in the upper arm. Study participants will include 39 healthy adults aged 18-40
years who have not been exposed to malaria and who will enroll at the Emory Vaccine and
Treatment Evaluation Unit in Atlanta, Georgia. Study procedures include physical exams and
several blood samples. Participants will be involved in the study for approximately seven and
one half months.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)